Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | solute carrier family 6 (neurotransmitter transporter), member 3 | Starlite/ChEMBL | No references |
Homo sapiens | solute carrier family 6 (neurotransmitter transporter), member 2 | Starlite/ChEMBL | No references |
Homo sapiens | solute carrier family 6 (neurotransmitter transporter), member 4 | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Brugia malayi | Sodium:neurotransmitter symporter family protein | solute carrier family 6 (neurotransmitter transporter), member 3 | 620 aa | 579 aa | 33.2 % |
Brugia malayi | Sodium:neurotransmitter symporter family protein | solute carrier family 6 (neurotransmitter transporter), member 2 | 617 aa | 638 aa | 32.5 % |
Brugia malayi | Sodium:neurotransmitter symporter family protein | solute carrier family 6 (neurotransmitter transporter), member 4 | 630 aa | 574 aa | 31.5 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Leishmania major | beta tubulin | 0.0214 | 0.627 | 1 |
Leishmania major | beta tubulin | 0.0214 | 0.627 | 1 |
Schistosoma mansoni | sodium/chloride dependent transporter | 0.0292 | 1 | 1 |
Loa Loa (eye worm) | tubulin beta-2A chain | 0.0214 | 0.627 | 0.627 |
Loa Loa (eye worm) | tubulin beta chain | 0.0214 | 0.627 | 0.627 |
Leishmania major | beta tubulin | 0.0214 | 0.627 | 1 |
Schistosoma mansoni | tubulin subunit beta | 0.0214 | 0.627 | 0.627 |
Schistosoma mansoni | norepinephrine/norepinephrine transporter | 0.0292 | 1 | 1 |
Echinococcus granulosus | Tubulin beta 2C chain | 0.0214 | 0.627 | 0.627 |
Trypanosoma brucei | beta tubulin | 0.0214 | 0.627 | 1 |
Echinococcus multilocularis | beta tubulin | 0.0214 | 0.627 | 0.627 |
Trichomonas vaginalis | tubulin beta chain, putative | 0.0214 | 0.627 | 1 |
Brugia malayi | beta-tubulin, identical | 0.0214 | 0.627 | 0.627 |
Echinococcus multilocularis | Tubulin beta 2C chain | 0.0214 | 0.627 | 0.627 |
Toxoplasma gondii | beta-1 tubulin, putative | 0.0214 | 0.627 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0292 | 1 | 1 |
Echinococcus multilocularis | tubulin subunit beta | 0.0214 | 0.627 | 0.627 |
Schistosoma mansoni | tubulin subunit beta | 0.0214 | 0.627 | 0.627 |
Trichomonas vaginalis | tubulin alpha chain, putative | 0.0214 | 0.627 | 1 |
Leishmania major | beta tubulin | 0.0214 | 0.627 | 1 |
Leishmania major | beta tubulin | 0.0214 | 0.627 | 1 |
Echinococcus multilocularis | tubulin beta 1 chain | 0.0214 | 0.627 | 0.627 |
Echinococcus granulosus | Tubulin beta 2C chain | 0.0214 | 0.627 | 0.627 |
Plasmodium falciparum | tubulin beta chain | 0.0214 | 0.627 | 1 |
Echinococcus multilocularis | beta tubulin | 0.0214 | 0.627 | 0.627 |
Echinococcus multilocularis | Tubulin beta 2C chain | 0.0214 | 0.627 | 0.627 |
Loa Loa (eye worm) | serotonin transporter b | 0.0292 | 1 | 1 |
Trypanosoma brucei | beta tubulin | 0.0214 | 0.627 | 1 |
Loa Loa (eye worm) | beta-tubulin | 0.0214 | 0.627 | 0.627 |
Treponema pallidum | sodium- and chloride- dependent transporter | 0.0292 | 1 | 0.5 |
Loa Loa (eye worm) | norepinephrine transporter | 0.0292 | 1 | 1 |
Echinococcus granulosus | Tubulin beta 2C chain | 0.0214 | 0.627 | 0.627 |
Echinococcus multilocularis | tubulin, beta 4A class IVa | 0.0214 | 0.627 | 0.627 |
Leishmania major | beta tubulin | 0.0214 | 0.627 | 1 |
Echinococcus multilocularis | Tubulin beta 2C chain | 0.0214 | 0.627 | 0.627 |
Leishmania major | beta tubulin | 0.0214 | 0.627 | 1 |
Leishmania major | beta tubulin | 0.0214 | 0.627 | 1 |
Loa Loa (eye worm) | BEN-1 protein | 0.0214 | 0.627 | 0.627 |
Echinococcus granulosus | beta tubulin | 0.0214 | 0.627 | 0.627 |
Echinococcus multilocularis | Tubulin beta 2C chain | 0.0214 | 0.627 | 0.627 |
Giardia lamblia | Beta tubulin | 0.0214 | 0.627 | 1 |
Leishmania major | beta tubulin | 0.0214 | 0.627 | 1 |
Trypanosoma cruzi | beta tubulin, putative | 0.0214 | 0.627 | 1 |
Leishmania major | beta tubulin | 0.0214 | 0.627 | 1 |
Toxoplasma gondii | beta tubulin | 0.0214 | 0.627 | 1 |
Schistosoma mansoni | tubulin subunit beta | 0.0214 | 0.627 | 0.627 |
Echinococcus granulosus | beta tubulin | 0.0214 | 0.627 | 0.627 |
Brugia malayi | Tubulin beta-1 chain | 0.0214 | 0.627 | 0.627 |
Leishmania major | beta tubulin | 0.0214 | 0.627 | 1 |
Trichomonas vaginalis | tubulin, putative | 0.0214 | 0.627 | 1 |
Leishmania major | beta tubulin | 0.0214 | 0.627 | 1 |
Toxoplasma gondii | beta-tubulin, putative | 0.0214 | 0.627 | 1 |
Loa Loa (eye worm) | BEN-1 protein | 0.0214 | 0.627 | 0.627 |
Schistosoma mansoni | tubulin subunit beta | 0.0214 | 0.627 | 0.627 |
Leishmania major | beta tubulin | 0.0214 | 0.627 | 1 |
Loa Loa (eye worm) | solute carrier family 6 member 4 | 0.0292 | 1 | 1 |
Leishmania major | beta tubulin | 0.0214 | 0.627 | 1 |
Onchocerca volvulus | 0.0292 | 1 | 0.5 | |
Trypanosoma brucei | beta tubulin | 0.0214 | 0.627 | 1 |
Giardia lamblia | Beta tubulin | 0.0214 | 0.627 | 1 |
Schistosoma mansoni | tubulin subunit beta | 0.0214 | 0.627 | 0.627 |
Loa Loa (eye worm) | hypothetical protein | 0.0292 | 1 | 1 |
Loa Loa (eye worm) | tubulin beta-1 chain | 0.0214 | 0.627 | 0.627 |
Echinococcus granulosus | tubulin beta 4A class IVa | 0.0214 | 0.627 | 0.627 |
Plasmodium vivax | tubulin beta chain, putative | 0.0214 | 0.627 | 1 |
Echinococcus multilocularis | Tubulin beta 2C chain | 0.0214 | 0.627 | 0.627 |
Echinococcus granulosus | Tubulin beta 2C chain | 0.0214 | 0.627 | 0.627 |
Giardia lamblia | Beta tubulin | 0.0214 | 0.627 | 1 |
Echinococcus granulosus | Tubulin beta 2C chain | 0.0214 | 0.627 | 0.627 |
Schistosoma mansoni | tubulin subunit beta | 0.0214 | 0.627 | 0.627 |
Trichomonas vaginalis | tubulin gamma chain, putative | 0.0214 | 0.627 | 1 |
Trypanosoma brucei | beta tubulin | 0.0214 | 0.627 | 1 |
Echinococcus granulosus | tubulin beta 1 chain | 0.0214 | 0.627 | 0.627 |
Echinococcus granulosus | tubulin subunit beta | 0.0214 | 0.627 | 0.627 |
Leishmania major | beta tubulin | 0.0214 | 0.627 | 1 |
Loa Loa (eye worm) | tubulin beta-4 chain | 0.0214 | 0.627 | 0.627 |
Echinococcus multilocularis | serotonin transporter | 0.0292 | 1 | 1 |
Leishmania major | beta tubulin | 0.0214 | 0.627 | 1 |
Trichomonas vaginalis | tubulin epsilon chain, putative | 0.0214 | 0.627 | 1 |
Leishmania major | beta tubulin | 0.0214 | 0.627 | 1 |
Leishmania major | beta tubulin | 0.0214 | 0.627 | 1 |
Trichomonas vaginalis | tubulin epsilon chain, putative | 0.0214 | 0.627 | 1 |
Echinococcus granulosus | serotonin transporter | 0.0292 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0292 | 1 | 1 |
Entamoeba histolytica | tubulin family protein | 0.0214 | 0.627 | 1 |
Entamoeba histolytica | tubulin family protein | 0.0214 | 0.627 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Ki (binding) | = 470 nM | BindingDB_Patents: Binding Assay. In order to evaluate the relative affinity of the various compounds at the NE, DA and 5HT transporters, HEK293E cell lines were developed to express each of the three human transporters. cDNAs containing the complete coding regions of each transporter were amplified by PCR from human brain libraries. The cDNAs contained in pCRII vectors were sequenced to verify their identity and then subcloned into an Epstein-Barr virus based expression plasmid (Shen et al., Gene 156:235-239 (1995), which is hereby incorporated by reference in its entirety). This plasmid containing the coding sequence for one of the human transporters was transfected into HEK93E cells. Successful transfection was verified by the ability of known reuptake blockers to inhibit the uptake of tritiated NE, DA or 5HT.For binding, cells were homogenized, centrifuged, and then resuspended in incubation buffer (5 mM Tris, 120 mM NaCl, 5 mM KCl, pH 7.4). Then, the appropriate radioligand was added. | ChEMBL. | No reference |
Ki (binding) | = 1375 nM | Binding Assay | BINDINGDB. | No reference |
Ki (binding) | = 2787 nM | Binding Assay | BINDINGDB. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.